• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Frontline Breast Cancer Approval Could Be A Big Moment For Pfizer Stock (PFE)

    Simply Wall St·10/10/2026 14:36:01
    語音播報
    • Pfizer received U.S. FDA approval for TUKYSA in combination with trastuzumab and pertuzumab as chemotherapy free maintenance therapy in frontline unresectable locally advanced or metastatic HER2+ breast cancer, supported by Phase 3 data showing a 35.9% reduction in the risk of disease progression or death versus placebo based regimens.
    • This earlier line TUKYSA use broadens Pfizer's oncology treatment footprint into HER2+ metastatic breast cancer maintenance and adds another marketed option that aligns with the wider push toward targeted, chemotherapy sparing regimens and may influence how resources are allocated across its cancer portfolio.
    • We will look at how Pfizer's broader frontline TUKYSA approval fits into the existing investment narrative around oncology led diversification.

    Scan how Pfizer's new TUKYSA approval fits into the broader oncology story, and then compare it with 28 high quality undervalued stocks that may also be building targeted cancer franchises.

    Pfizer Investment Narrative Recap

    To own Pfizer, you need to believe the pivot away from COVID products toward oncology, obesity and immunology can offset patent losses and softer revenue, while cost cuts support margins. The new frontline TUKYSA approval fits that story by deepening Pfizer’s cancer footprint, but it does not change that the near term remains a reset period.

    The main near term swing factor stays the same: execution on US$9.7b of planned savings and the ramp of launched and acquired drugs. The biggest risk continues to be weaker pricing or slower uptake that leaves earnings squeezed, especially with a high dividend, meaningful debt and revenue expected to decline over the next few years.

    Among the recent headlines, the most relevant alongside TUKYSA is Pfizer’s broad oncology data presence at the 2026 ESMO Congress, covering PADCEV, TALZENNA and late stage agents like atirmociclib and tivunatamig. That breadth reinforces that TUKYSA is one piece of a wider effort to shift the mix toward targeted cancer therapies.

    For you as an investor, that oncology buildout sits next to other pipeline work in obesity and dermatology as key potential offsets to declining COVID sales and upcoming loss of exclusivity. The opportunity is clear, but so are the execution risks. Each positive data set or approval helps the story. Any clinical or regulatory setback would quickly stress it.

    What the TUKYSA Approval Sits On Top Of: Pfizer’s Current Analyst Framework

    Pfizer's oncology push, including the new TUKYSA use in HER2+ metastatic breast cancer, now has to work against a backdrop where analysts are still modeling shrinking top line revenue and rising profitability. Consensus assumptions point to revenue declining by 5.2% a year over the next three years, even as profit margins are expected to expand from 6.8% today to 16.8% within that same window. That combination suggests that, on the Street, the focus is less on rapid sales expansion and more on mix shift, cost discipline and higher contribution from targeted therapies like TUKYSA, rather than COVID products.

    Earnings expectations build on that same mix change. Analysts see Pfizer's earnings today at about US$4.3b and are modeling a move to US$9.1b by 2029, with earnings per share at US$1.67 around that time. That would roughly double profit in dollar terms, even though the number of shares is only expected to grow by about 0.25% per year for the next three years. On that math, oncology, obesity and immunology need to carry much more of the load alongside cost savings, while declining COVID sales and loss of exclusivity pressures act in the other direction.

    Pfizer's narrative projects US$54.3b revenue and US$9.1b earnings by 2029. This is based on analyst expectations for revenue to decline 5.2% per year and implies an earnings increase of about US$4.8b from US$4.3b today.

    Valuation work from analysts then ties those earnings and margin ideas back to the share price you see today. The consensus view points to a price target of US$28.88, only 2.6% above the recent US$28.12 share price. To get there, the group expects Pfizer to reach that US$54.3b in revenue and US$9.1b in earnings by 2029 and trade on a P/E of 22.5x, which is higher than the current US pharmaceuticals industry P/E of 15.3x. That premium multiple depends on investors believing in the earnings mix shift toward oncology, obesity and other non COVID products as well as the US$9.7b cost saving plan.

    The spread in analyst targets also matters if you are sizing risk around Pfizer. The most bullish target sits at US$35.75 and the most cautious at US$25.00, which brackets different views on how quickly new cancer drugs and obesity treatments contribute and how reliably margin expansion can be delivered. Underneath that, there is even wider disagreement on future earnings, with projections for 2029 ranging from US$6.7b to US$12.5b. That range gives a sense of how much weight each analyst assigns to pipeline execution, TUKYSA-like oncology approvals and pricing headwinds.

    For an investor weighing the TUKYSA news, this framework offers a reference point rather than a script. If you think oncology assets such as TUKYSA, PADCEV and TALZENNA can support stronger earnings than the US$9.1b consensus and justify a premium P/E over time, the current fair value calls might look cautious. If you are more concerned about drug pricing moves, slower oncology uptake or COVID stepping down faster than non COVID products build, even a relatively modest upside to the consensus price target may not feel like enough compensation.

    Uncover why Pfizer's fair value is in line with its current price.

    NYSE:PFE 1-Year Stock Price Chart
    NYSE:PFE 1-Year Stock Price Chart

    Exploring Other Perspectives

    You might see the new TUKYSA move and focus on upside, yet the lowest Pfizer forecasts leaned hard into pricing risk. Those analysts were working with revenue falling 7.6% a year and earnings of only US$6.7b by 2029. That is a much more cautious story. Use this approval as a prompt to compare both narratives carefully.

    Explore 11 other Pfizer fair value estimates, including one that suggests there could be as much as 12% downside from the current price.

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking for more investment ideas beyond Pfizer?

    If the TUKYSA approval has sharpened your view on Pfizer but you also want a wider watchlist, the Simply Wall St Screener can help you surface other stocks that fit different risk and return profiles.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.